Dupont Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-2,374
| Closed | -$284K | – | 1046 |
|
|
2022
Q4 | $284K | Sell |
2,374
-435
| -15% | -$51K | 0.01% | 694 |
|
|
2022
Q3 | $298K | Sell |
2,809
-1,023
| -27% | -$104K | 0.02% | 762 |
|
|
2022
Q2 | $374K | Sell |
3,832
-906
| -19% | -$83.6K | 0.02% | 818 |
|
|
2022
Q1 | $444K | Buy |
4,738
+1,620
| +52% | +$137K | 0.02% | 816 |
|
|
2021
Q4 | $266K | Sell |
3,118
-3,212
| -51% | -$295K | 0.01% | 1014 |
|
|
2021
Q3 | $607K | Sell |
6,330
-2,233
| -26% | -$211K | 0.02% | 785 |
|
|
2021
Q2 | $833K | Buy |
8,563
+5,015
| +141% | +$481K | 0.02% | 712 |
|
|
2021
Q1 | $345K | Buy |
3,548
+2,399
| +209% | +$252K | 0.01% | 1103 |
|
|
2020
Q4 | $110K | Hold |
1,149
| – | – | ﹤0.01% | 1203 |
|
|
2020
Q3 | $110K | Sell |
1,149
-1,732
| -60% | -$200K | ﹤0.01% | 1188 |
|
|
2020
Q2 | $351K | Buy |
+2,881
| New | +$318K | 0.01% | 922 |
|
|
2019
Q4 | – | Sell |
-2,056
| Closed | -$185K | – | 1275 |
|
|
2019
Q3 | $185K | Buy |
+2,056
| New | +$192K | ﹤0.01% | 1109 |
|
|
2019
Q1 | – | Sell |
-3,500
| Closed | -$250K | – | 1225 |
|
|
2018
Q4 | $250K | Sell |
3,500
-9,412
| -73% | -$902K | 0.01% | 980 |
|
|
2018
Q3 | $1.59M | Buy |
12,912
+7,961
| +161% | +$903K | 0.04% | 447 |
|
|
2018
Q2 | $486K | Sell |
4,951
-4,264
| -46% | -$382K | 0.01% | 715 |
|
|
2018
Q1 | $764K | Sell |
9,215
-86,748
| -90% | -$7.33M | 0.02% | 586 |
|
|
2017
Q4 | $7.45M | Buy |
95,963
+23,466
| +32% | +$1.6M | 0.17% | 120 |
|
|
2017
Q3 | $4.44M | Buy |
72,497
+59,843
| +473% | +$3.16M | 0.1% | 203 |
|
|
2017
Q2 | $582K | Buy |
12,654
+6,734
| +114% | +$327K | 0.01% | 649 |
|
|
2017
Q1 | $256K | Sell |
5,920
-8,759
| -60% | -$375K | 0.01% | 796 |
|
|
2016
Q4 | $568K | Buy |
14,679
+12,528
| +582% | +$567K | 0.01% | 628 |
|
|
2016
Q3 | $109K | Sell |
2,151
-9,919
| -82% | -$494K | ﹤0.01% | 643 |
|
|
2016
Q2 | $549K | Buy |
12,070
+6,926
| +135% | +$319K | 0.01% | 561 |
|
|
2016
Q1 | $203K | Sell |
5,144
-22,006
| -81% | -$873K | ﹤0.01% | 609 |
|
|
2015
Q4 | $1.54M | Buy |
27,150
+3,030
| +13% | +$154K | 0.04% | 388 |
|
|
2015
Q3 | $960K | Hold |
24,120
| – | – | 0.02% | 455 |
|
|
2015
Q2 | $1.15M | Buy |
24,120
+9,000
| +60% | +$382K | 0.02% | 416 |
|
|
2015
Q1 | $600K | Sell |
15,120
-7,910
| -34% | -$283K | 0.01% | 493 |
|
|
2014
Q4 | $514K | Sell |
23,030
-9,960
| -30% | -$189K | 0.01% | 545 |
|
|
2014
Q3 | $517K | Hold |
32,990
| – | – | 0.01% | 556 |
|
|
2014
Q2 | $490K | Sell |
32,990
-5,890
| -15% | -$83.1K | 0.01% | 580 |
|
|
2014
Q1 | $626K | Sell |
38,880
-35,477
| -48% | -$607K | 0.01% | 569 |
|
|
2013
Q4 | $694K | Sell |
74,357
-11,517
| -13% | -$112K | 0.01% | 542 |
|
|
2013
Q3 | $972K | Buy |
85,874
+27,922
| +48% | +$384K | 0.02% | 489 |
|
|
2013
Q2 | $775K | Buy |
+57,952
| New | +$712K | 0.01% | 497 |
|
Other funds holding NBIX
BG
DM
Dupont Capital Management's NBIX Position: Q1 2023 in Review
Dupont Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 2,374 shares — an estimated $284K sold.
Dupont Capital Management first reported a position in NBIX in Q2 2013 and held it in 35 quarters. The position peaked at $7.45M in Q4 2017. 487 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.
- Dupont Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
- Dupont Capital Management sold 2,374 Neurocrine Biosciences shares in Q1 2023, an estimated $284K.
- Dupont Capital Management first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 35 quarters.
- Dupont Capital Management's Neurocrine Biosciences position peaked at $7.45M in Q4 2017.
- 487 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.
Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.